SQZ Biotechnologies’ Market continues Uptrend, following last week’s FDA Fast Track Designation announcement – 247MarketNews.com

SQZ Biotechnologies’ Market continues Uptrend, following last week’s FDA Fast Track Designation announcement – 247MarketNews.com

On April 27, 2022, after the market closed, SQZ Biotechnologies (NYSE: SQZ) announced that the FDA granted Fast Track Designation for the company’s lead cell therapy candidate, SQZ-PBMC-HPV, for the treatment of HPV16+ advanced or metastatic solid tumors.

The Fast Track Designation potentially allows SQZ to sell its SQZ Antigen Presenting Cells product candidate to patients earlier and accelerate the development and review of treatments for serious and life-threatening diseases where no treatment currently exists or where the treatment in discovery may be better than what is currently available.

Click here for the SQZ press release

JOIN OUR NEWSLETTER

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist